OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis $0.09 0.00 (0.00%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Provectus Biopharmaceuticals alerts: Email Address About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PVCT alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range$0.08▼$0.1352-Week Range$0.04▼$0.22Volume166,555 shsAverage Volume266,795 shsMarket Capitalization$37.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Read More… The Perfect Storm for an EV Revolt (Ad)With constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves... Not many people realize there’s a "perfect storm" for profits unfolding in the auto industry - today. Or that cars and trucks are actually the world’s biggest business. Click here for details... Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PVCT Stock News HeadlinesProvectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual MeetingMay 21, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual MeetingMay 14, 2024 | finance.yahoo.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 20, 2024 | Timothy Sykes (Ad)Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationApril 16, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal SodiumMarch 27, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and VaccinesMarch 12, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual MeetingMarch 7, 2024 | globenewswire.comSee More Headlines PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed this year? Provectus Biopharmaceuticals' stock was trading at $0.0960 at the beginning of the year. Since then, PVCT stock has decreased by 6.3% and is now trading at $0.09. View the best growth stocks for 2024 here. How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA) and Energy Transfer (ET). Company Calendar Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CUSIPN/A CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,100,000.00 Net Margins-407.89% Pretax Margin-408.04% Return on EquityN/A Return on Assets-219.95% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.10 Sales & Book Value Annual Sales$560,000.00 Price / Sales67.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-4.50Miscellaneous Outstanding Shares419,910,000Free Float365,823,000Market Cap$37.79 million OptionableNot Optionable Beta0.59 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (OTCMKTS:PVCT) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.